Determination of the Incidence of Tuberculosis in Low-Income Countries
To the Editor-We read with interest the report by The Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA) and The ART Cohort Collaboration on tuberculosis (TB) after initiation of antiretroviral therapy in low-income and high-income countries [1] . The authors do not mention the number of patients who were already receiving treatment for TB when the antiretroviral therapy was started (were the data not available?). However, they do mention that programs in lower-income countries routinely screened patients for TB before they commenced HAART. It is unclear to us whether patients being given treatment for TB at the start of HAART were included in the analysis. We propose that they should have been excluded from the study population if the aim of the study was to determine the incidence of TB and to compare the incidence rateratios for new TB infections. Indeed, in contrast to in high-income countries, in low-income countries, TB is one of the main reasons to initiate HAART. In Malawi, for example, from July through September 2005, 12% of the patients who started HAART did so because of TB [2] . During treatment for TB, by definition these patients cannot develop a new TB infection. We suppose that, if this approach were taken, the conclusions of the report would remain the same, but the calulations may change slightly. If the number of patients not receiving treatment for TB who started HAART is used as the denominator, the real incidence of TB in low-income countries will be even higher, particularly soon after the initiation of HAART.
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Reply to Colebunders and Caluwaerts
To the Editor-We thank Colebunders and Caluwaerts [1] for their interest in the recent analysis by The Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA) and The ART Cohort Collaboration [2] . In this collaborative study, we compared the incidence rates of tuberculosis (TB) among patients receiving HAART in low-income and high-income countries. Colebunders and Caluwaerts ask whether the analysis included patients who were receiving treatment for TB at the start of HAART and argue that, if so, this might have biased the incidence rates of TB downward in lower-income countries and might have distorted the incidence-rate ratios during the firs year of HAART. As Caluwaerts and Colebunders [1] suspected, data on treatment for TB at the time of initiation of HAART were not available for all the cohorts from low-income countries. But note that, as we pointed out in our report [2] , the main objective of the analysis was not to estimate absolute rates but was to compare relative changes in rates of TB during the firs year of HAART in low-income and high-income settings. The incidence rates obtained in such an analysis of data from 15 different sites were a weighted average of site-specifi rates, influence by variation in background rates and diagnostic procedures, and are not applicable to any specifi setting.
We repeated analyses for 9 low-income cohorts with data on previous treatment for TB, including 2050 patients who were not receiving treatment when HAART was started. Among these patients, the incidence of TB in the firs year of HAART was 8.8 cases per 100 person-years (95% CI, 7.5-10.3 cases per 100 person-years), which is slightly higher than the 7.4 cases per 100 person-years (95% CI, 6.6-8.4 cases per 100 person-years) reported in the previously published analysis [2] . As predicted by Caluwaerts and Colebunders [1] , this difference was more pronounced during the firs 3 months of treatment: 13.9 cases per 100 person-years (95% CI, 11.0-17.6 cases per 100 person-years) in this analysis, compared with 10.7 cases per 100 person-years (95% CI, 8.9-12.9 cases per 100 person-years) in the original analysis. The decrease in the incidence rate during the firs year of HAART was, however, similar for the 2 analyses. Compared with the rate for months 1-3, the rate ratio was 0.65 (95% CI, 0.44-0.96) for months 4-6 and was 0.39 (95% CI, 0.27-0.58) for months 7-12. The corresponding ratios from the original analysis were 0.70 (95% CI, 0.52-0.94) and 0.48 (95% CI, 0.36-0.64), respectively. Interestingly, the inci- 1.9 (0.8-5) 2.9 (0.9-9.4) VMIC 2.0 2.6 (0.9-8) 6.4 (1.7-24.3) NA 2.3 (0.9-6) 3.6 (1.2-10.9) NOTE. Data are summarized from the article by Soriano et al. [1] . NA, receipt of inappropriate empirical therapy; VMIC 1.0, receipt of empirical vancomycin and an isolate with a vancomycin MIC of 1 mg/mL; VMIC 1.5, receipt of empirical vancomycin and an isolate with a vancomycin MIC of 1.5 mg/mL; VMIC 2.0, receipt of empirical vancomycin and an isolate with a vancomycin MIC of 2 mg/mL. dence-rate ratios from this analysis are somewhat closer to those reported for the high-income cohorts in the original analysis [2] . The sensitivity analysis prompted by the letter from Caluwaerts and Colebunders thus strengthens our conclusions that the reduction in rates of TB during the firs year of HAART is similar in lowincome and high-income settings.
